Menu
← Oncology Approval Tracker
FDA DECISION ·
Abecma
idecabtagene vicleucel · Bristol Myers Squibb / bluebird bio
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with relapsed or refractory multiple myeloma after four or more prior treatment lines that included an immunomodulatory drug, a proteasome inhibitor and an anti-CD38 monoclonal antibody.
LAMPGEN ANALYSIS
Why it matters
The original BCMA-directed CAR T action targeted previously treated myeloma after exposure to three drug classes.
What research teams should watch
Collect prior regimens and coordinate referral, leukapheresis, manufacture, infusion and post-infusion monitoring.
PRIMARY RECORDS